groups of patients who are young and healthy; however, these often differ substantially on one or more critical factors selecting appropriate medications for the frail elderly.
medications relevant to Thus, the
information derived from studies on taken from trials of younger adults evidence supporting the safe and unstudied patient population.
the benefits and the risks of drugs did not contribute quality clinical effective use of Risperdal for an
In April 2003, Janssen sent out a "Dear Healthcare Provider" letter indicating that Risperdal (1) enhanced the risk of cerebrovascular events such as strokes and (2) was neither safe nor effective when prescribed for dementia-related psychosis.
system was designed in such a way that it was unable to flag patients with a medical history
indicating that Risperdal was not a preferred medication. This was one of the reasons that the
Risperdal switch was not implemented at Jacobs. However, the switch was implemented at other
additional names, dates, times, and places relating to the negotiation and implementation of the
illegal Market Share Agreement is solely within the possession of Janssen and Omnicare,
Lisitza's superiors conceded the existence, implementation, and financial impact of the Risperdal
Market Share Agreement to Lisitza and instructed him about what he was required to do to
accomplish the financial objective of the Risperdal Market Share Agreement.
thousands of prescriptions switched at other Omnicare facilities pursuant to the Risperdal Market
dispensing pharmacies, pharmacy benefit managers, and hospitals, to illegally gain market share
for Risperdal in the atypical antipsychotic market through illegal kickbacks-for-switches